Evidence map›Paper›PMID 38505825›Full record

ArticleJournal of pharmaceutical policy and practice2024

Odds and associated factors for thrombosis development among Lebanese COVID-19 patients: a case-control retrospective study.

Mahmoud Youness, Sara Mansour, Fouad Sakr, Samer Olabi, Sarah Atwi, Iman Younes Martinez, Sami El Khatib, Souheil Hallit, Pascale Salameh, Diana Malaeb and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 9 countries.

Mahmoud YounessResearch Department, Beirut Cardiac Institute, Beirut, Lebanon.
Sara MansourSchool of Pharmacy, Lebanese International University, Beirut, Lebanon.
Fouad SakrSchool of Pharmacy, Lebanese International University, Beirut, Lebanon.
Samer OlabiRafic Hariri University Hospital, Beirut, Lebanon.
Sarah AtwiRafic Hariri University Hospital, Beirut, Lebanon.
Iman Younes MartinezFaculty of Medicine, Lebanese University, Beirut, Lebanon.
Sami El KhatibDepartment of Biomedical Sciences, Lebanese International University, Bekaa, Lebanon.
Souheil HallitSchool of Medicine and Medical Sciences, Holy Spirit University of Kaslik, Jounieh, Lebanon.
Pascale SalamehINSPECT-LB: Institut National de Santé Publique, Epidémiologie Clinique et Toxicologie, Beirut, Lebanon.
Diana MalaebCollege of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates.
Hassan HosseiniNeurology Department, Henri Mondor Hospital, AP-HP, Creteil, France.
Rafik Hariri University Hospital · LBGulf Medical University · AEGulf University for Science & Technology · KWHoly Spirit University of Kaslik · LBInternational University · KHLebanese International University · LBLebanese University · LBOrient-Institut Beirut · LBRégie Autonome Multi Services D'Agadir · MAUniversity of Nicosia · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Thromboembolism is reported to be up to 27% in COVID-19 patients due to SARS-CoV-2 infection. Dysregulated systemic inflammation and various patient traits play a vital role in thrombosis progression. Purpose: To assess odds and associated factors for thrombosis development among Lebanese COVID-19 patients. Methods: This was a case-control retrospective study conducted in January-May 2021. Patients infected with COVID-19 and developed thrombosis were classified as cases and patients who were thrombosis-free identified as control. A questionnaire assessed socio-demographics, clinical parameters, and WHO COVID-19 disease severity. Results: Among 267 patients, 26 (9.7%) developed thrombosis and the majority of thrombosis 34.6% was myocardial infarction, and the least (3.8%) was for catheter-related thrombosis. Results showed that the risk of thrombosis development is higher in patients with previous thromboembolic event (OR = 9.160) and previous intake of anti-hypertensive medications at home (OR = 3.116). However, females (OR = 0.330; CI: 0.118-0.925), intake of anticoagulants during hospital admission (OR = 0.126; CI: 0.053-0.300) and non-severe COVID-19 were at lower thrombosis risk (OR = 0.273). Patients who developed thromboembolic events had longer hospital stay (OR = 0.077). Conclusion: Patients with COVID-19 and thromboembolism were at higher risk of mortality as compared to patients with COVID-19 but without thromboembolism. The use of anticoagulants significantly reduced the risk for thromboembolism.

Indexed as

COVID-19deathfactors associatedhospitalisationthromboembolism

Identifiers

PMID38505825
PMCPMC10950289
OpenAlexW4392811383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.